Opdivo (nivolumab) | Friends of Cancer Research

You are here

Opdivo (nivolumab)

Sponsor: 
Bristol-Myers Squibb Company
Indication: 
Patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
Category: 
Year: 
2018
Date: 
Feb 10th
FDA Status: 
FDA Approval
Approval Date: 
Jun 10th
Approval Year: 
2018